Development of a Bead-Based Multiplex Genotyping Method for Diagnostic Characterization of HPV Infection

Mee Young Chung¹, Yong-Wan Kim², Su Mi Bae², Eun Hye Kwon², Pankaj Kumar Chaturvedi², Gantumur Battogtokh², Woong Shick Ahn³*

¹ Department of Anesthesiology, College of Medicine, The Catholic University of Korea, Seocho-ku, Seoul, Korea, ² Cancer Research Institute of Medical Science, The Catholic University of Korea, Seocho-ku, Seoul, Korea, ³ Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seocho-ku, Seoul, Korea

Abstract
The accurate genotyping of human papillomavirus (HPV) is clinically important because the oncogenic potential of HPV is dependent on specific genotypes. Here, we described the development of a bead-based multiplex HPV genotyping (MPG) method which is able to detect 20 types of HPV (15 high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 and 5 low-risk HPV types 6, 11, 40, 55, 70) and evaluated its accuracy with sequencing. A total of 890 clinical samples were studied. Among these samples, 484 were HPV positive and 406 were HPV negative by consensus primer (PGMY09/11) directed PCR. The genotyping of 484 HPV positive samples was carried out by the bead-based MPG method. The accuracy was 93.5% (95% CI, 91.0–96.0), 80.1% (95% CI, 72.3–87.9) for single and multiple infections, respectively, while a complete type mismatch was observed only in one sample. The MPG method indiscriminately detected dysplasia of several cytological grades including 71.8% (95% CI, 61.5–82.3) of ASCUS (atypical squamous cells of undetermined significance) and more specific for high grade lesions. For women with HSIL (high grade squamous intraepithelial lesion) and SCC diagnosis, 32 women showed a PPV (positive predictive value) of 77.3% (95% CI, 64.8–89.8). Among women ≥40 years of age, 22 women with histological cervical cancer lesions showed a PPV of 88% (95% CI, 75.3–100). Of the highest risk HPV types including HPV-16, 18 and 31 positive women of the same age groups, 34 women with histological cervical cancer lesions showed a PPV of 77.3% (95% CI, 65.0–89.6). Taken together, the bead-based MPG method could successfully detect high-grade lesions and high-risk HPV types with a high degree of accuracy in clinical samples.

Introduction
Human papillomavirus (HPV) infection is associated with a variety of clinical conditions, ranging from asymptomatic infections to benign and malignant diseases of the genital mucosa [1]. In the only extensively studied host, humans, nearly 100 HPV types have been described based on the isolation of the complete genome [2]. The HPV types have been grouped into high risk and low risk HPV types according to their potential to cause invasive cancer [3]. Studies of the oncogenic potential of HPV have clearly demonstrated that high risk HPV types are a necessary cause for the development of cervical cancer [4].

Currently there are two main molecular approaches used for HPV detection: the polymerase chain reaction (PCR) with generic primers used to amplify part of the L1 gene of the viral capsid, which is highly conserved among anogenital HPVs, and the Hybrid Capture II test (HCII; Digene, Gaithersburg, MD, USA), which detects 13 high risk HPV types including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. The HCII allows quantification of the HPV DNA load, but lacks information on the HPV genotype. Since the oncogenic potential differs among the high risk HPV types [5–7], viral genotyping, following high risk HPV detection, might be useful for better risk stratification of high risk positive women. The general PCR-based methods followed by PGMY line blot [8] and LiPA line blot [9], targeting the L1 region of the HPV genome, enable the precise identification of the HPV genotypes present in samples. However, these assays are restricted to a maximum of about 40 oligonucleotide probes per hybridization reaction due to the format of the line blot strips and depend on a visual read-out of the signal [10]. In addition, none of these assays can be automated or deployed on a high-throughput platform, features that are essential for an assay intended for use with a large volume of patients.

Luminex (xMAP) suspension array technology is based on polystyrene beads that are internally dyed with various ratios of two spectrally distinct fluorophores. Different molecules such as individual oligonucleotide probes can be coupled to different bead sets with specific absorption spectra. These sets are combined to a suspension array and allow up to 100 different probes to be measured simultaneously in a single reaction (multiplexing). This technology can potentially be fully automated, dramatically decreasing the personal cost component of the assay; this assay has been used for the genotyping of 45 HPV types with PGMY09/11 PCR [11], 22 HPV types with GP5+/6+ PCR [10], 15 HPV types with YBT L1/GP-1 PCR [12], and 18 HPV types with
Sensitivity and specificity of the bead-based MPG method

The bead-based MPG method basically uses the MFI of the reporter fluorescence for HPV genotyping. That is, positivity of the respective types is calculated from the MFI over a defined cutoff value and can provide a semi-quantitative numerical output. For the calculation of the cutoff value, the biotinylated PGMY09/11 amplimers generated from 200 ng of the HPV negative human DNA were hybridized after one step PCR (see Materials and Methods for detail). The background value was in the range from 50 MFI to 135 MFI depending on the HPV probes used (Table S1). The detection limits were determined by using HPV plasmids with serial dilution based on the cutoff value of 150 MFI as shown in Figure 1B. The bead-based MPG method successfully detected HPV 16 at 50 plasmid copies while HPV 40 was detected even at five plasmid copies. Less than five thousand plasmids were sufficient for the detection of all 20 HPV types using one step reaction.

To determine the ability of the bead-based MPG method to specifically detect different HPV types, the 20 type-specific probes and the GAPDH probe were coupled individually to defined bead sets (“21-plex”) and hybridized to PMGY09/11 amplimers generated from 1x10⁶ copies of HPV plasmids and 200 ng of genomic DNA from HeLa cells known to be HPV 18 positive. Positivity for the respective types was calculated from the MFI over their cutoff values. The PMGY09/11 PCR amplicons of the HeLa cells showed a high MFI value only in for the HPV 18 probe. There was a 10 fold higher MFI for GAPDH than the other PMGY09/11 PCR amplicons without GAPDH genomic DNA (Table 1). In addition, no significant cross-hybridization signals were generated by the PCR amplicons of individual HPV plasmids. These findings indicate good discrimination with the one step PCR product generated by the biotinylated PGMY09/11 primers.

Analysis of clinical samples and comparison with Sequencing

As shown in Figure 1C, the performance of the bead-based MPG was tested on 484 clinical samples that were PGMY09/11 PCR product positive and the accuracy was verified by sequencing. The bead-based method detected 383 single infections and 101 multiple infections. For the single infections, the 16 HPV genotypes including HPV-6, 11, 18, 31, 35, 40, 45, 56, 59, 66, and 70 showed 100% accuracy while the lowest accuracy (55.6%) was observed for HPV 68 (Table 2). The accuracy for HPV-16, the most common HPV type, was 98.1% even with its high number of samples compared to the other HPV types. The other common single infections were HPV-18, HPV-53 and HPV-58, and the accuracies of these types were 100%, 81.6%, and 87.1%, respectively.

The accuracy of the bead-based MPG method was also estimated for multiple infections (Table S2). The verification of multiple infections was performed by sequencing with the respective type-specific primer. Eighty percent of the total of multiple infections showed a perfect match while a complete type mismatch was observed only in one sample. The double infections containing HPV-16 and 18 accounted for 37.6% of the total number of multiple infections. The double infections containing only low risk HPV types were found in only 5.6% of the samples. The MPG method indiscriminately detected dysplasia of several grade cytology including 71.8% of ASCUS (atypical squamous cells of undetermined significance) and more specific for high grade lesions as shown in Table 3. Of the total women with a positive HPV result and a histological diagnosis (n = 271) including all age groups, 90 women had histological cervical cancer lesions (CIN2+), giving a PPV of 32.3%. For women with HSIL and SCC diagnosis, 32 of 43 women having histological CIN2+ showed a PPV of 74.4%. Among women >40 years of age, the data showed that 22 of 25 women with the same histology showed a PPV of 88%. Of the highest risk HPV types including HPV-16, 18 and 31 positive women of all age groups, 62 of 88 women had a diagnosis of CIN2+, giving a PPV of 70.4% as shown in Table 4. Among women >40 years of age, 34 of 44 women with the same histology showed a PPV of 77.3% (Table 5). This result suggests that with a higher PPV of the test and high-grade histological diagnosis, the MPG method is an important tool in detecting women with the high-grade lesions or high risk HPV types.

The HPV genotyping by the bead-based method and sequencing showed almost perfect agreement (k = 0.935; 95% CI, 0.91–0.96); while the k values for the detection of HPV 16 and 18 were 0.99 and 0.96, respectively. In addition, the sensitivity, specificity and accuracy of the bead-based MPG method were 90.7%, 100%, and 94.9%, respectively, for the detection of high risk HPVs when the genotype information given by sequencing was used as the standard. This suggests that the bead-based MPG method could successfully detect HPV infections and identify HPV genotypes with a high degree of accuracy.

Discussion

Accurate HPV genotyping has become an important prognostic indicator in the clinical screening of women due to the strong casual relationship between persistent HPV infection and high grade cervical intraepithelial neoplasia [18,19]. In cervical screening programs, HPV DNA is typically detected by a non-radioactive signal amplification method, the Hybrid Capture II
assay (HC2; Digene Co, Gaithersburg, Md., USA) which allows for the detection of 13 probable high risk and five low risk HPV types using two different cocktails of RNA probes, in two reactions [20]. HC2 is at present the only Food and Drug Administration-approved assay for routine detection of HPV infections [21]. The HC2 assay provides information on the viral load, which is useful in detecting recurrences after treatment of cervical intraepithelial neoplasia 3 and micro-invasive cancer as well as the response to radiation therapy for cervical cancer [22,23]. However, the HC2 does not provide information on the specific type of HPV detected. In addition, it is less sensitive than the PCR-based method and the cross-reactivity of the two cocktail probes decreases the clinical specificity of a positive result [20]. The sensitivity and the specificity of HPV DNA can be improved by PCR-based methods including restriction fragment length polymorphism (RFLP) assays, reverse hybridization analysis, microarray platforms and/or sequencing. Among these methods, sequencing is the “gold standard” for HPV genotyping, in which HPV DNA is amplified with primers such as GP5+/6+ (consensus) or MY09/11 (degenerate) followed by sequencing. Since the HPV genotyping by sequencing is the most accurate method, it is desirable to evaluate the accuracy of any HPV genotyping method on the basis of the sequencing results [16,17]. In this study, the one step PCR product generated by the biotinylated PGMY09/11 primer showed good discrimination for 484 HPV positive samples and evaluated by sequencing. The accuracy of the MPG method was 93.5% (95% CI, 91.0–96.0) and 80.1% (95% CI, 72.3–87.9) for single and multiple infections, respectively. This indicates that the HPV genotype of clinical samples could be successfully identified by the bead-based MPG method with a high degree of accuracy and one step reaction.

In most studies, the HPV genotyping accuracy in multiple infections has not been evaluated because the conventional direct sequencing cannot resolve the identity of genotypes in samples containing multiple infections in which viral sequences overlap [16,24,25]. Recent study showed that sequencing was able to identify types in only four cases of multiple infection, which were those having only two virus types in the sample [26]. In the multiple infection, the sequencing yields nonspecific amplification products, which causes nonspecific and uninterruptible sequencing data. Therefore, it was suggested that both sequencing and type-specific PCR could be employed as a genotyping strategy for HPV genotyping.

Figure 1. Overall scheme of multiplex bead-based assay and its representative multiplexing results. A) Assay workflow of a bead-based multiplex HPV genotyping (MPG) method showing the general steps required to detect 20 types of HPV. B) Standard curves for the multiplexed HPV genotyping assays in a 96-well microplate format results. The detection limits were determined by using HPV plasmids with serial dilution based on the cutoff value of 150 MFI. C) Dot plot obtained from microspheres encoded with intensities of two fluorochromes. The number is for each type of HPV. The white circles represent each bead type’s spectral address; a flow cytometer classifies the bead type and amount of PCR product attached to each bead’s surface, expressed as MFI. The sample injection volume was 50 ul, and the system was set to count 100 events for each of the color-coded beads. While the Luminex beads fall within their respective regions for detection and counting, the larger particles fall near the bottom of the graph, and do not interfere with Luminex particle detection and counting. Increasing density is indicated by contrasting colors.

doi:10.1371/journal.pone.0032259.g001
in clinical practice. In this study, multiple infections were confirmed by repeated sequencing analysis with type-specific primers. The high accuracy of the bead-based MPG method in multiple infections might be due to the efficient hybridization kinetics of Luminex suspension array, which closely approximates the kinetics of solution-phase hybridization [11] and results in short hybridization times and faster turn-around times that is possible with the DNA chip. In addition, the quality of the bead-based MPG method is more controllable than with the DNA chip; this is because its performance can be tested by sampling the master array of beads.

This study also showed that 89.3% (95% CI, 86.2–92.4) of single infections were caused by high risk types; the three main high risk types were HPV-16, 18, and 53. In the contrast to other studies [15,27], the frequency of HPV-53 was as high as HPV-18. This suggests that HPV-53 might also play an important role in multiple infections. Multiple infections might carry a lower risk for malignant progression than single infections with high risk types of HPV, due to the suppressive effect of E2 protein by a type of HPV on E6 and E7 ORFs of another type HPV; because a significantly higher proportion of double infections were detected in women with normal or inflamed cervixes than among women with cervical intraepithelial neoplasia 1 or higher severity [32]. However, the number of HPV types showed a significant relationship with the PPV of the cervical intraepithelial neoplasia grade. Of the highest risk HPV types including HPV-16, 18 and 31 positive women >40 years of age, 34 of 44 women with histology had a diagnosis of CIN2+, giving a PPV of 77.3% (95% CI, 66.7–89.6). (70.4% for women of all age). In this case, HPV 16 positive women have a PPV for CIN2+ of 80.6% (95% CI, 66.7–94.6), suggesting that HPV 16 positive women can get a better clinical safety by direct treatment.

In this study, such relationships with multiple infections and cervical intraepithelial neoplasia grade were also observed. The PPV for HPV positive women with ASCUS is higher than the PPV for women with normal cytology, indicating that the consistency might be due to the high accuracy of the bead-based genotyping method with enough sample numbers. Among women >40 years of age, the PPV of the diagnoses HSIL and SCC for CIN2+ was higher for types 6, 11, 16, 18, 31, 33, 51, 52, and 56 where all types except for types 6 and 11 are high risk HPV [31]. This indicates that the high risk type of HPV might play an important role in multiple infections. Multiple infections might carry a lower risk for malignant progression than single infections with high risk types of HPV, due to the suppressive effect of E2 protein by a type of HPV on E6 and E7 ORFs of another type HPV; because a significantly higher proportion of double infections were detected in women with normal or inflamed cervixes than among women with cervical intraepithelial neoplasia 1 or higher severity [32]. However, the number of HPV types showed a significant relationship with the PPV of the cervical intraepithelial neoplasia grade. Of the highest risk HPV types including HPV-16, 18 and 31 positive women >40 years of age, 34 of 44 women with histology had a diagnosis of CIN2+, giving a PPV of 77.3% (95% CI, 66.7–89.6). (70.4% for women of all age). In this case, HPV 16 positive women have a PPV for CIN2+ of 80.6% (95% CI, 66.7–94.6), suggesting that HPV 16 positive women can get a better clinical safety by direct treatment.

In this study, such relationships with multiple infections and cervical intraepithelial neoplasia grade were also observed. The PPV for HPV positive women with ASCUS is higher than the PPV for women with normal cytology, indicating that the consistency might be due to the high accuracy of the bead-based genotyping method with enough sample numbers. Among women >40 years of age, the PPV of the diagnoses HSIL and SCC for CIN2+ were 93.3% and 80.0% respectively. This suggests that women >40 years of age with HSIL and a positive HPV test can be directly referred to treatment. HPV 16 positive women have a PPV for CIN2+ of 78.1% when including all age groups, as shown.

Table 1. Type specificity of the bead-based MPG method.

| 20 HPV type and HeLa cells | GAPDH probe and HPV type-specific probe |
|----------------------------|----------------------------------------|
|                           | GAPDH 6 11 16 18 31 33 35 39 40 45 51 52 53 55 56 58 59 66 68 70 |
| HeLa                     | 96 10 21 12 6650 15 14 18.5 17 88 15 8 20 22 19 10 14.5 28.5 24 19 22 |
| 6                        | 14 5194 73 40 36 18 38 93.5 73 52 40 16 25.5 73 40.5 29 47 105.5 37.5 72 42.5 |
| 11                       | 7 9 4079 24 12.5 11.5 17.5 55 33 35 20 9 12.5 37.5 30 16 23 48 18.5 30.5 34.5 |
| 16                       | 6 6.5 18 4781 13 12 15 21.5 19 19 13 9 12 16.5 11 9 14.5 29 12 20 12 |
| 18                       | 6 9 16 15.5 5751 10 12 30 24 17 11 6 10.5 18 11 9 13 31 10.5 19 14 |
| 31                       | 7.5 10 19.5 20 9.5 2623 13 26 22 18 10 8 12 20 11 10 15 35.5 14 24 13 |
| 33                       | 5 7 15 21.5 15 11.5 4903 28.5 21 18 12.5 6.5 11.5 23.5 13 9 15 37 14.5 20 14 |
| 35                       | 8 11 27 26.5 15 15 21 6456 34 22.5 17 8.5 13 32 19 13 17 68 24 31 19 |
| 39                       | 10 13 27 30.5 12 13 20 44.5 2961 20 21 10 18 37 20.5 12 22.5 53 21 36 22.5 |
| 40                       | 8 8 20.5 20 11.5 13 17.5 34.5 28 7172 18 8 15.5 24 19 11 21 45 15.5 26 19 |
| 45                       | 6.5 6 18 22 11.5 9 11 21 23 82 3598 7 8 14 13 10 9 33 14 17 11 |
| 51                       | 7 8 18 18 13 11 9 27 17.5 20 8 6449 13 19 11 9 12 42.5 15 14 |
| 52                       | 5 9 14 16 10 10.5 9 22 17 91 12 5 1485 21 10 7 10 32 10 14.5 13 |
| 53                       | 5 8 17 21 8 14 11 23 19 85 11 4 13 4631 10 8 11.5 31 12 22 12 |
| 55                       | 7 9 19 21 8 10 14 26 27 18 14 8 12 23 2536 10 14 41 12 25 15 |
| 56                       | 8 8 13 16 9 9 9 19 16.5 14 9 5 10 13 6 4443 11 26.5 12 18 9 |
| 58                       | 3.5 9 24 14 11 13 4 34 39 138 15 8 12 27 14.5 10 2535 48 18.5 30 15 |
| 59                       | 5 6 12 12 7 10 8 46 14 11 9.5 7 12 14 8 8 8 5457 11 15.5 8 |
| 66                       | 9 8 17 15 10 14 15 22 20 19 9 7 11 17.5 8 9 16 28 2007 20 11 |
| 68                       | 3 6 12 12 7.5 10 10 18 17 51 9 5 8 15 7.5 6 9 24 10 5771 9 |
| 70                       | 9 16 26 15 14 18 17 39 32 14 17 3 13 26 11 10 12 52 17.5 30 5325 |

doi:10.1371/journal.pone.0032259.t001
representing a higher PPV than 68.9% of the cytological HSIL diagnosis, while the PPV of the other HPV types is lower. Thus, these findings suggest that the bead-based MPG method showed a higher clinical specificity and positive predictive value, specially for CIN2+. For the fundamental understanding of multiple infections and patient follow up for CIN2+ [33], the specific biological features of individual HPV types such as integration status and RNA expression, might be also needed [34]. In addition, a study on the interaction among different HPV types is necessary for achieving better understanding of multiple infections. HPV-HPV interactions might occur through indirect interactions that result from alterations of the host environment or immunological interactions in addition to the direct interactions of HPV genes or gene products.

The accurate genotyping of human papillomavirus is clinically important because the oncogenic activity of HPV is dependent on the specific genotypes. Although HPV genotyping by sequencing is the most accurate method, it is the most labor intensive and time-consuming. Therefore, the ideal HPV genotyping method should have genotyping accuracy comparable to sequencing and be automated or deployed on a high-throughput platform, features essential for an assay intended for a large volume of patients. Our findings suggest that the bead-base MPG method is a valuable strategy for an efficient HPV genotyping and risk stratification of women with a positive HPV test.

Materials and Methods

Ethics statement

All patients involved in the study had signed a declaration of consent stating that the patients specimens may be used for scientific intentions. Specimens were obtained from the patients in the Department of Obstetrics and Gynecology in concordance with procedures approved by the Institutional Review Board of The Catholic University of Korea (07BR238).

Table 2. The accuracy of the bead-based MPG method in single infections.

| HPV genotype | No. of positive samples with bead-base MPG | No. of samples confirmed by sequencing | Accuracy (%) |
|-------------|------------------------------------------|--------------------------------------|--------------|
| 6           | 13                                       | 13                                   | 100.0        |
| 11          | 4                                        | 4                                    | 100.0        |
| 16          | 105                                      | 103                                  | 98.1         |
| 18          | 31                                       | 31                                   | 100.0        |
| 31          | 15                                       | 15                                   | 100.0        |
| 33          | 7                                        | 6                                    | 85.7         |
| 35          | 10                                       | 10                                   | 100.0        |
| 39          | 16                                       | 15                                   | 93.8         |
| 40          | 2                                        | 2                                    | 100.0        |
| 45          | 3                                        | 3                                    | 100.0        |
| 51          | 19                                       | 16                                   | 84.2         |
| 52          | 25                                       | 23                                   | 92.0         |
| 53          | 38                                       | 31                                   | 81.6         |
| 55          | 4                                        | 3                                    | 75.0         |
| 56          | 20                                       | 20                                   | 100.0        |
| 58          | 31                                       | 27                                   | 87.1         |
| 59          | 4                                        | 4                                    | 100.0        |
| 66          | 9                                        | 9                                    | 100.0        |
| 68          | 9                                        | 5                                    | 55.6         |
| 70          | 18                                       | 18                                   | 100.0        |
| Total number | 383                                      | 358                                  | 93.5         |

doi:10.1371/journal.pone.0032259.t002

Table 3. Total women with a positive HPV test and a histological diagnosis.

| Cytology | Total with this diagnosis | HPV positives | Women with CIN2+ among the HPV positives | Women with a histology diagnosis | PPV for CIN2+ (95% CI) |
|----------|---------------------------|---------------|------------------------------------------|--------------------------------|------------------------|
| Normal   | 222                       | 94            | 27                                       | 115                            | 23.4 (15.6–31.1)       |
| ASCUS    | 71                        | 51            | 15                                       | 46                             | 32.6 (19.1–46.1)       |
| LSIL     | 88                        | 80            | 16                                       | 74                             | 21.6 (12.2–310)        |
| HSIL     | 32                        | 32            | 20                                       | 29                             | 68.9 (52.1–85.7)       |
| SCC      | 15                        | 14            | 12                                       | 14                             | 85.7 (67.4–100.0)      |
| Total    | 428                       | 271           | 90                                       | 278                            | 32.3 (26.8–37.8)       |

| Women >40 years of age | Total with this diagnosis | HPV positives | Women with CIN2+ among the HPV positives | Women with a histology diagnosis | PPV for CIN2+ (95% CI) |
|------------------------|---------------------------|---------------|------------------------------------------|--------------------------------|------------------------|
| Normal                | 90                        | 42            | 14                                       | 59                             | 23.7 (12.8–34.6)       |
| ASCUS                 | 40                        | 28            | 8                                        | 25                             | 32.0 (13.7–50.3)       |
| LSIL                  | 38                        | 36            | 5                                        | 36                             | 13.8 (2.53–25.1)       |
| HSIL                  | 20                        | 20            | 14                                       | 15                             | 93.3 (80.65–100.0)     |
| SCC                   | 10                        | 9             | 8                                        | 10                             | 80.0 (55.2–100.0)      |
| Total                 | 198                       | 135           | 49                                       | 145                            | 33.8 (24.7–39.9)       |

ASCUS, atypical squamous cells of undetermined significance.  
LSIL, low grade squamous intraepithelial lesion.  
HSIL, high grade squamous intraepithelial lesion.  
SCC, squamous cell cervical carcinoma.  
CIN2+, higher cervical intraepithelial neoplasia.  
doi:10.1371/journal.pone.0032259.t003
Samples and isolation of DNA

A total of 890 cervical samples were tested for HPV detection with the patient’s permission, in the Department of Obstetrics and Gynecology, The Catholic University of Korea. Cervical swabs were obtained with a Cerex-Brush® (Pappete, Wallach Surgical Devices, Inc., Orange, CT, USA). The brush was immediately rinsed in a vial of PreservCyt® solution (Cytyc Corpor., Boxborough, MA, USA). To isolate DNA, two millimeters of cell suspension was transferred to a 2-ml reaction tube and washed twice by centrifugation at 14,000 rpm for 2 min, followed by removal of the supernatant and resuspension of the pellet in 1 ml of phosphate-buffered saline. The pellet was resuspended in 200 μl of phosphate-buffered saline and used for DNA isolation with the Qiagen blood DNA minikit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.

Plasmid clones

For the evaluation of specificity and cross hybridization of the bead-based MPG method, plasmid clones of the following 20 HPV

| Table 4. Total women with a different HPV test and a histological diagnosis. |
|-------------------------------|----------------------|---------------------------|----------------------|------------------|
| **High risk HPV type** | **HPV positives** | **Women with CIN2+ among the HPV positives** | **Women with a histology diagnosis** | **PPV for CIN2+ (95% CI)** |
| 16 | 105 | 50 | 64 | 78.1 (68.0–88.3) |
| 18 | 31 | 9 | 18 | 50.0 (26.9–73.1) |
| 31 | 15 | 3 | 6 | 50.0 (10.0–90.0) |
| 33 | 7 | 4 | 5 | 80.0 (44.9–100.0) |
| 35 | 10 | 1 | 2 | 50.0 (0.0–100.0) |
| 39 | 16 | 0 | 9 | 0 |
| 45 | 3 | 0 | 0 | - |
| 51 | 19 | 1 | 7 | 14.3 (0.0–40.2) |
| 52 | 25 | 2 | 13 | 15.4 (0.0–35.0) |
| 53 | 38 | 1 | 15 | 6.7 (0.0–19.3) |
| 56 | 20 | 0 | 8 | 0 |
| 58 | 31 | 5 | 11 | 45.5 (16.0–74.9) |
| 59 | 4 | 0 | 2 | 0 |
| 66 | 9 | 1 | 6 | 16.7 (0.0–46.5) |
| 68 | 5 | 1 | 4 | 25.0 (0.0–67.4) |
| **total** | **342** | **78** | **170** | **45.9 (38.4–53.4)** |

doi:10.1371/journal.pone.0032259.t004

| Table 5. Women >40 years of age with a different HPV test and a histological diagnosis. |
|-------------------------------|----------------------|---------------------------|----------------------|------------------|
| **High risk HPV type** | **HPV positives** | **Women with CIN2+ among the HPV positives** | **Women with a histology diagnosis** | **PPV for CIN2+ (95% CI)** |
| 16 | 36 | 25 | 31 | 80.6 (66.7–94.6) |
| 18 | 13 | 6 | 10 | 60.0 (29.6–90.4) |
| 31 | 4 | 3 | 3 | 100 |
| 33 | 4 | 2 | 3 | 66.7 (13.3–100) |
| 35 | 4 | 1 | 2 | 50.0 (0.0–100) |
| 39 | 3 | 0 | 2 | 0 |
| 45 | 1 | 0 | 0 | - |
| 51 | 8 | 2 | 8 | 25.0 (0.0–55.0) |
| 52 | 6 | 1 | 6 | 16.7 (0.0–46.5) |
| 53 | 13 | 0 | 13 | 0 |
| 56 | 4 | 0 | 4 | 0 |
| 58 | 13 | 5 | 10 | 50.0 (19.0–81.0) |
| 59 | 2 | 0 | 2 | 0 |
| 66 | 5 | 1 | 5 | 20.0 (0.0–55.1) |
| 68 | 4 | 1 | 2 | 50.0 (0.0–100) |
| **total** | **120** | **47** | **101** | **46.5 (36.8–56.3)** |

doi:10.1371/journal.pone.0032259.t005
types were used: 6, 11, 16, 18, 31, 33, 35, 39, 40, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68 and 70.

Oligonucleotide probes for HPV genotyping

The type-specific oligonucleotide probes were designed for 20 different HPV types (15 high-risk HPV types including 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68 and 5 low-risk HPV types including 6, 11, 40, 55, 70) on the basis of the DNA sequences of the viral L1 gene, which were obtained from the HPV database (http://hpv-web.lanl.gov/) (Table S3). All probes had 5'-amine modification for bead coupling as well as 15 bp oligo-dT sequences attached for hybridization flexibility.

Amplification of the L1 fragment and its labeling

Amplification of the L1 gene on 200 ng of genomic DNA isolated from cervical samples was carried out with the biotinylated PGMY09/11 primer set. PCR conditions were the same as published in the PGMY 09/11 version [6]. For a positive control of the PCR, two primers were used for amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sequences: GAPDH F, 5′-GAGTCAACGGATTTGGTCGT-3′ for the forward primer and GAPDH R, 5′-TTGATTTTTGGAGGCATCCTG-3′ for the reverse primer. Since the copy number of the GAPDH gene in the clinical sample was usually higher than that of the HPV, the GAPDH primer concentration was reduced to one fourth of the PGMY09/11 primer concentration. A biotinylated primer set was used for one step PCR reaction. The PCR components in 20 μL PCR mixture were 0.025 μM biotinylated PGMY09/11 primer, 40 μM dATP, dGTP, dTTP mixture, 10 μM biotin-11-dCTP (Invitrogen, Carlsbad, CA, USA), 75 mM Tris HCl (pH 9.0), 20 mM MgCl₂, 50 mM KCl, 20 mM (NH₄)₂SO₄, and 1.5 U Taq polymerase (Biotools, Madrid, Spain). A 5-min denaturation step at 94°C was followed by a 40-cycle denaturation step at 94°C for 1 min, an annealing step at 55°C for 1 min and an elongation step at 72°C for 1 min.

Coupling of oligonucleotide probes to beads

The type-specific oligonucleotide probes were 5'-amine modified and then were coupled to carboxylated beads (Luminex Corp., Austin, TX, USA) through a carbodiimide base coupling procedure. Preparation of the beads coupled with oligonucleotide followed a procedure reported previously [12]. Each bead carrying the type-specific oligonucleotide was finally mixed in equal proportion. Here, this mixture is referred to as the bead mix.

Hybridization assay

Hybridization buffer (21 μL of 2 × EZway Hybrisol; Koma Co., Seoul, Korea) and 1 μL of HPV bead mix containing 6.75 × 10⁴ beads (2.5 × 10⁵ for each HPV type and control) were added to a labeling tube containing the PCR product. The hybridization was conducted as previously reported [12]. After hybridization, the samples were transferred to a filter plate immediately and washed three times with washing buffer (0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0) at room temperature. The beads were resuspended for 15 min in 100 μL of streptavidin-R-phycocerythrin (Strep-PE; Molecular Probes, Eugene, OR, USA) and analyzed for internal bead color and R-phycocerythrin receptor fluorescence on a Luminex 100 analyzer. The median reporter fluorescence intensity (MFI) of at least 100 beads was computed for each bead set in the sample.

Sequencing

The amplified L1 gene with the PGMY09/11 primer set was purified with the QIAquick PCR Purification Kit (Qiagen) according to the manufacturer’s instructions. Sequencing was performed using the BigDye Terminator v3.1 cycle sequencing kit with AmpliTaq DNA polymerase (Applied Biosystems) according to the protocols supplied by the manufacturer with type-specific primers. The sequences obtained from the sequencing were compared with the HPV sequences of known types using the basic local alignment search tool from the NCBI website (http://www.ncbi.nlm.nih.gov/BLAST).

Cutoff definition and statistical analysis

Reactions of the probes with the PCR products derived from the PGMY09/11 PCR on 200 ng of HPV negative genomic DNA was considered the background values. In this study, the HPV negative genomic DNA was extracted from the human cervical cancer cell line C33A. The background was calculated by the mean value of 19 replicates and the cut-off value was 150 MFI, which is slightly higher than the highest background of 135 MFI, for all HPV probes. Agreement between the bead-based MPG method and sequencing was assessed by the Cohen κ statistic, with values of 0.00 to 0.20 indicating poor agreement; 0.21 to 0.40, fair agreement; 0.41 to 0.60, moderate agreement; 0.61 to 0.8, substantial agreement; and 0.81 to 1.00 almost perfect agreement.

Supporting Information

Table S1 Detection limits of 20 type-specific probes used for the bead-based MPG method.

(DOC)

Table S2 The comparison of the results of HPV genotyping with DNA sequencing.

(DOC)

Table S3 Type-specific oligonucleotide probes for 20 HPV genotypes.

(DOC)

Acknowledgments

We thank HyoJoo Bang for Luminex analysis and technical assistance.

Author Contributions

Conceived and designed the experiments: MYC YWK WSA. Performed the experiments: EHK SMB. Analyzed the data: YWK EHK SMB. Contributed reagents/materials/analysis tools: PKC GB. Wrote the paper: MYC YWK WSA.

References

1. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63–73.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324: 17–27.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527.
4. Lauthien M, Luukkala T, Wallin KL, Pauwens J, Thorsen S, et al. (2001) Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol 22: 117–124.
5. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, et al. (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072–1079.
6. Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, et al. (2006) Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 15: 1260–1273.

7. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade EJ, et al. (2007) High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 96: 1419–1424.

8. Gravitt PE, Prentice CL, Alesi TQ, Wheeler CM, Goullee F, et al. (2000) Improved amplification of genital human papillomaviruses. J Clin Microbiol 38: 357–361.

9. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, et al. (1999) Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomaviruses. J Clin Microbiol 37: 2508–2517.

10. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pavlita M, et al. (2000) Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 304–312.

11. Wallace J, Woda BA, Pihan G (2005) Facile, comprehensive, high-throughput genotyping of human genital papillomaviruses using spectrally addressable liquid bead microarrays. J Mol Diagn 7: 72–80.

12. Oh Y, Bae SM, Kim YW, Choi HS, Nam GH, et al. (2007) Polymerase chain reaction-based fluorescent Luminex assay to detect the presence of human papillomavirus types. Cancer Sci 98: 549–554.

13. Geeraerts DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, et al. (2009) High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+ PCR and xMAP technology. J Clin Virol 46 Suppl 3: S21–S26.

14. Milutin Gasperov N, Sabol I, Matovina M, Spaventi S, Grce M (2008) Detection and typing of human papillomaviruses combining different methods: polymerase chain reaction, restriction fragment length polymorphism, line probe assay and sequencing. Pathol Oncol Res 14: 355–363.

15. Kim KH, Yoon MS, Na VJ, Park CS, Oh MR, et al. (2006) Development and evaluation of a highly sensitive human papillomavirus genotyping DNA chip. Gynecol Oncol 100: 38–43.

16. Vernon SD, Unger ER, Williams D (2000) Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol 38: 651–655.

17. Asato T, Maehama T, Nagai Y, Kanazawa K, Urzato H, et al. (2004) A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 189: 1829–1832.

18. Brink AA, Snijders PJ, Meijer CJ (2007) HPV detection methods. Dis Markers 25: 273–281.

19. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M (2000) Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113: 1900–1993.

20. Nobre RJ, de Almeida LP, Martins TC (2008) Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm. J Clin Virol 42: 13–21.

21. Hubbard RA (2005) Human papillomavirus testing methods. Arch Pathol Lab Med 129: 940–945.

22. Datta NR, Kumar P, Singh S, Gupta D, Srivastava A, et al. (2006) Does pretreatment human papillomavirus (HPV) titers predict radiation response and survival outcomes in cancer cervix? A pilot study. Gynecol Oncol 103: 100–105.

23. Park JY, Lee SM, Yoo CW, Kang S, Park SY, et al. (2007) Risk factors predicting residual disease in subsequent hysterectomy following conization for cervical intraepithelial neoplasia (CIN) III and microinvasive cervical cancer. Gynecol Oncol 107: 39–44.

24. Choi YD, Jung WW, Nam JH, Choi HS, Park CS (2005) Detection of HPV genotypes in cervical lesions by the HPV DNA Chip and sequencing. Gynecol Oncol 98: 369–373.

25. Gharizadeh B, Kalantari M, Garcia CA, Johansson B, Nyren P (2001) Typing of human papillomavirus by pyrosequencing. Lab Invest 81: 673–679.

26. Carvalho Nde O, del Castillo DM, Perone C, Januario JN, Melo VH, et al. (2010) Comparison of HPV genotyping by type-specific PCR and sequencing. Mem Inst Oswaldo Cruz 105: 73–78.

27. Bae HJ, Lee SJ, Kim CJ, Hur SY, Park YG, et al. (2008) Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. J Microbiol Biotechnol 18: 788–794.

28. Trotter H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, et al. (2006) Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 15: 1274–1280.

29. Wheeler CM, Hunt WC, Schiffman M, Castle PE (2006) Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 194: 1291–1299.

30. Law KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, et al. (2001) A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183: 8–15.

31. Spinillo A, Dal Bello B, Alberitzza P, Cesari S, Gardella B, et al. (2009) Clustering patterns of human papillomavirus genotypes in multiple infections. Virus Res 142: 154–159.

32. Chan PK, Li VH, Chan MY, Ma WL, Cheung JL, et al. (1999) High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 59: 232–236.

33. Zhao Y, Lin H, Shen D, Xuan Y, Lin Z (2008) Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. Pathol Int 58: 643–647.

34. Boulet GA, Horvath CA, Berghmans S, Bogers J (2008) Human papillomavirus infection in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev 17: 810–817.